Are you "Profiting from the Pros?"
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
Eli Lilly Up on Positive Ramucirumab Data
Eli Lilly and Company’s ( LLY - Analyst Report) shares were up 5.14% after the company announced encouraging data from a phase III study on its oncology candidate, ramucirumab.
The worldwide, randomized, double-blind REVEL study compared the use of ramucirumab in combination with Sanofi’s ( SNY - Analyst Report) Taxotere (docetaxel) to Taxotere plus placebo in second-line non-small cell lung cancer (NSCLC) patients.
Data from the study, revealed a statistically significant improvement in overall survival (primary endpoint of the study) and progression-free survival in the ramucirumab plus Taxotere arm versus the Taxotere and placebo arm. The company plans to submit regulatory applications for ramucirumab based on data from the REVEL study in 2014.
Eli Lilly is also evaluating ramucirumab for other types of cancer including gastric, hepatocellular (liver) and colorectal cancer. The company is looking to get ramucirumab approved as a monotherapy in gastric cancer in the U.S. and the EU. Eli Lilly intends to file for approval of the ramucirumab and paclitaxel combination for patients suffering from gastric cancer in 2014. Meanwhile, top-line data from phase III studies evaluating the candidate for hepatocellular and colorectal cancer are expected in 2014.
We remind investors that Eli Lilly gained the rights to ramucirumab through the acquisition of ImClone Systems in 2008. Our Take
We are pleased with the positive data from the REVEL study on ramucirumab. We believe that ramucirumab possess blockbuster potential and if approved will provide a must needed boost to Eli Lilly’s revenues. Revenues of two key products, Cymbalta (already lost exclusivity in the U.S.) and Evista (Mar 2014), are expected to decline significantly this year due to generic competition.
Eli Lilly is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks include Forest Laboratories and Auxilium Pharmaceuticals Ltd. . Both carry a Zacks Rank #1 (Strong Buy).